{"pmid":32385891,"title":"Systemic Immunobiological, Immunosuppressant and Oncologic Agents for the Treatment of Dermatologic Diseases during the SARS-Cov-2 (COVID19) Pandemic Emergency: a Quick Review for a Quick Consultation.","text":["Systemic Immunobiological, Immunosuppressant and Oncologic Agents for the Treatment of Dermatologic Diseases during the SARS-Cov-2 (COVID19) Pandemic Emergency: a Quick Review for a Quick Consultation.","The Precision Medicine Era has helped to better manage patients with immunological and oncological disease, improving the quality of life of this class of patients. Regarding the management of these patients and positivity to SARS-Cov2, currently, limited data is available and information is evolving. In this quick review we have analyzed the mechanisms of action and related infective risk of drugs used for the treatment of immune-mediated and oncologic skin conditions during the daily clinical practice. In general immunosuppressant and antineoplastic agents for dermatologic treatments do not require suspension and do not require special measures, if not those commonly observed. In the case of a COVID19 patient with complication (such as pneumonia, respiratory failure), treatment suspension should always be considered after taking into account the general condition of the patient, the risk-benefit ratio and the pathophysiology of COVID19 infection. The COVID19 emergency pandemic does not imply an under-treatment of existing skin conditions, which together with the SARS-Cov2 infection may jeopardize the patient's life. This article is protected by copyright. All rights reserved.","Dermatol Ther","Paolino, Giovanni","Mercuri, Santo Raffaele","Bearzi, Pietro","Mattozzi, Carlo","32385891"],"abstract":["The Precision Medicine Era has helped to better manage patients with immunological and oncological disease, improving the quality of life of this class of patients. Regarding the management of these patients and positivity to SARS-Cov2, currently, limited data is available and information is evolving. In this quick review we have analyzed the mechanisms of action and related infective risk of drugs used for the treatment of immune-mediated and oncologic skin conditions during the daily clinical practice. In general immunosuppressant and antineoplastic agents for dermatologic treatments do not require suspension and do not require special measures, if not those commonly observed. In the case of a COVID19 patient with complication (such as pneumonia, respiratory failure), treatment suspension should always be considered after taking into account the general condition of the patient, the risk-benefit ratio and the pathophysiology of COVID19 infection. The COVID19 emergency pandemic does not imply an under-treatment of existing skin conditions, which together with the SARS-Cov2 infection may jeopardize the patient's life. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Paolino, Giovanni","Mercuri, Santo Raffaele","Bearzi, Pietro","Mattozzi, Carlo"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385891","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/dth.13537","topics":["Treatment","Prevention","Mechanism"],"weight":1,"_version_":1666340102086852608,"score":9.490897,"similar":[{"pmid":32436617,"title":"Immunosuppressive agents for dermatological indications in the ongoing COVID 19 pandemic: rationalizing use and clinical applicability.","text":["Immunosuppressive agents for dermatological indications in the ongoing COVID 19 pandemic: rationalizing use and clinical applicability.","The ongoing COVID 19 epidemic has brought to the fore many concerns related to use of immunosuppressive agents (ISAs) in dermatology. While it is unclear whether the patients on ISAs for skin conditions are more prone to develop COVID 19, and what impact the ISA may have on the clinical outcome if a patient does get infected, rationalizations based on the specific immune effects of each drug, and existing literature on incidence of various infections with each, are possible. In this review, we provide the readers with practically useful insights into these aspects, related to the conventional ISAs, and briefly mention the clinical outcome data available on related scenarios from other patient groups so far. In the end, we have attempted to provide some clinically useful points regarding practical use of each dermatologically relevant conventional ISA in the current scenario. This article is protected by copyright. All rights reserved.","Dermatol Ther","Khurana, Ananta","Saxena, Snigdha","32436617"],"abstract":["The ongoing COVID 19 epidemic has brought to the fore many concerns related to use of immunosuppressive agents (ISAs) in dermatology. While it is unclear whether the patients on ISAs for skin conditions are more prone to develop COVID 19, and what impact the ISA may have on the clinical outcome if a patient does get infected, rationalizations based on the specific immune effects of each drug, and existing literature on incidence of various infections with each, are possible. In this review, we provide the readers with practically useful insights into these aspects, related to the conventional ISAs, and briefly mention the clinical outcome data available on related scenarios from other patient groups so far. In the end, we have attempted to provide some clinically useful points regarding practical use of each dermatologically relevant conventional ISA in the current scenario. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Khurana, Ananta","Saxena, Snigdha"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436617","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/dth.13639","keywords":["covid-19","azathioprine","ciclosporine","cyclophosphamide","dermatology","immunology","immunosuppressive","methotrexate","mycophenolate","pathogenesis","steroids"],"topics":["Treatment"],"weight":1,"_version_":1667521393749655552,"score":257.6666},{"pmid":32458530,"title":"Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.","text":["Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.","Immunosuppressive and immunomodulatory therapies are important in dermatology, but indications are influenced by SARS-CoV-2. We will focus on are skin disorders such as autoimmune connective tissue disorders, neutrophilic dermatoses and vasculitis. Immunomodulators such as colchicine and antimalarials can easily be preferred taking their beneficial effects on Covid-19 into consideration and also given their wide spectrum of action. Among the conventional therapies, methotrexate, azathioprine and mycophenolate mofetil increase the risk of infection, and thus their use is recommended only when necessary and at low doses. On the other hand, use of cyclosporine is also not recommended as it increases the risk of hypertension, which is susceptible to Covid-19. Anti-TNF agents from among the biological therapies appear to be slightly risky in terms of susceptibility to infection. However, there are ongoing studies which suggest that some biological treatments may reduce cytokine storm impeding the Covid-19 progression as a result, in spite of their susceptibilities to Covid-19. Patients, who will be started on immunosuppressive therapy, should be tested for Covid-19 prior to the therapy, and in the event that Covid-19 is suspected, the therapy should be discontinued. This article is protected by copyright. All rights reserved.","Dermatol Ther","Karadag, Ayse Serap","Aslan Kayiran, Melek","Lotti, Torello","Wollina, Uwe","32458530"],"abstract":["Immunosuppressive and immunomodulatory therapies are important in dermatology, but indications are influenced by SARS-CoV-2. We will focus on are skin disorders such as autoimmune connective tissue disorders, neutrophilic dermatoses and vasculitis. Immunomodulators such as colchicine and antimalarials can easily be preferred taking their beneficial effects on Covid-19 into consideration and also given their wide spectrum of action. Among the conventional therapies, methotrexate, azathioprine and mycophenolate mofetil increase the risk of infection, and thus their use is recommended only when necessary and at low doses. On the other hand, use of cyclosporine is also not recommended as it increases the risk of hypertension, which is susceptible to Covid-19. Anti-TNF agents from among the biological therapies appear to be slightly risky in terms of susceptibility to infection. However, there are ongoing studies which suggest that some biological treatments may reduce cytokine storm impeding the Covid-19 progression as a result, in spite of their susceptibilities to Covid-19. Patients, who will be started on immunosuppressive therapy, should be tested for Covid-19 prior to the therapy, and in the event that Covid-19 is suspected, the therapy should be discontinued. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Karadag, Ayse Serap","Aslan Kayiran, Melek","Lotti, Torello","Wollina, Uwe"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458530","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/dth.13686","keywords":["covid-19","immunomodulatory drugs","immunosuppressive drugs","rare skin diseases"],"topics":["Treatment"],"weight":1,"_version_":1668141322645536769,"score":200.66417},{"pmid":32419721,"pmcid":"PMC7224642","title":"Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.","text":["Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.","The emergence of the COVID-19 pandemic led to significant uncertainty among physicians and patients about the safety of immunosuppressive medications used for the management of dermatologic conditions. We review available data on commonly used immunosuppressants and their effect on viral infections beyond COVID-19. Notably, the effect of some immunosuppressants on viruses related to SARS-CoV2, including SARS and MERS, has been previously investigated. In the absence of data on the effect of immunosuppressants on COVID-19, these data could be used to make clinical decisions on initiation and continuation of immunosuppressive medications during this pandemic. In summary, we recommend considering the discontinuation of oral JAK inhibitors and prednisone, considering the delay of rituximab infusion, and the careful continuation of cyclosporine, mycophenolate, azathioprine, methotrexate, and biologics in patients currently benefitting from such treatments.","Clin Dermatol","Galimberti, Fabrizio","McBride, Jeffrey","Cronin, Megan","Li, Yumeng","Fox, Joshua","Abrouk, Michael","Herbst, Alexander","Kirsner, Robert S","32419721"],"abstract":["The emergence of the COVID-19 pandemic led to significant uncertainty among physicians and patients about the safety of immunosuppressive medications used for the management of dermatologic conditions. We review available data on commonly used immunosuppressants and their effect on viral infections beyond COVID-19. Notably, the effect of some immunosuppressants on viruses related to SARS-CoV2, including SARS and MERS, has been previously investigated. In the absence of data on the effect of immunosuppressants on COVID-19, these data could be used to make clinical decisions on initiation and continuation of immunosuppressive medications during this pandemic. In summary, we recommend considering the discontinuation of oral JAK inhibitors and prednisone, considering the delay of rituximab infusion, and the careful continuation of cyclosporine, mycophenolate, azathioprine, methotrexate, and biologics in patients currently benefitting from such treatments."],"journal":"Clin Dermatol","authors":["Galimberti, Fabrizio","McBride, Jeffrey","Cronin, Megan","Li, Yumeng","Fox, Joshua","Abrouk, Michael","Herbst, Alexander","Kirsner, Robert S"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419721","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.clindermatol.2020.05.003","e_drugs":["Cyclosporine","Azathioprine","Prednisone","Rituximab","Mycophenolic Acid","Methotrexate"],"topics":["Treatment"],"weight":1,"_version_":1667159284363821056,"score":192.14479},{"pmid":32441360,"title":"Evaluation Of Dermatology Consultations In The Era Of COVID19.","text":["Evaluation Of Dermatology Consultations In The Era Of COVID19.","It has been reported that dermatology practices may be a vector for SARS-CoV-2 transmission and elective cases should be postponed during the pandemic period. In this context, studies on the change of patient profile in Dermatology outpatient clinic have been conducted. However, there was no study in the literature about dermatology consultations during the pandemic period. 147 Dermatology consultation cases in the era of COVID-19 pandemic between March 11, 2020 and May 4, 2020 were retrospectively evaluated. 24 patients (16.3%) had suspicion and signs of COVID during consultation (fever, cough, shortness of breath, etc.). 9 (37.5%) of these patients also had accompanying COVID-19 skin lesions (2 urticarial lesions, 2 livedo and necrosis, 2 maculopapular eruption, 2 vesicular rashes, 1 pseudo-chilblain). The number of cases that were suspected to have COVID-19 was statistically significantly higher in consultations requested by the emergency department and intensive care unit, while there were no suspected cases in outpatient clinic consultations (P = 0.001). 2 (1.4%) of these patients were diagnosed with COVID-19 confirmed by PCR within 2 weeks. We acknowledge that daily practice changes frequently during this period, but still our study provides a perspective to other dermatology clinics in terms of the requested dermatology consultations during the pandemic. This article is protected by copyright. All rights reserved.","Dermatol Ther","Temiz, Selami Aykut","Dursun, Recep","Daye, Munise","Ataseven, Arzu","32441360"],"abstract":["It has been reported that dermatology practices may be a vector for SARS-CoV-2 transmission and elective cases should be postponed during the pandemic period. In this context, studies on the change of patient profile in Dermatology outpatient clinic have been conducted. However, there was no study in the literature about dermatology consultations during the pandemic period. 147 Dermatology consultation cases in the era of COVID-19 pandemic between March 11, 2020 and May 4, 2020 were retrospectively evaluated. 24 patients (16.3%) had suspicion and signs of COVID during consultation (fever, cough, shortness of breath, etc.). 9 (37.5%) of these patients also had accompanying COVID-19 skin lesions (2 urticarial lesions, 2 livedo and necrosis, 2 maculopapular eruption, 2 vesicular rashes, 1 pseudo-chilblain). The number of cases that were suspected to have COVID-19 was statistically significantly higher in consultations requested by the emergency department and intensive care unit, while there were no suspected cases in outpatient clinic consultations (P = 0.001). 2 (1.4%) of these patients were diagnosed with COVID-19 confirmed by PCR within 2 weeks. We acknowledge that daily practice changes frequently during this period, but still our study provides a perspective to other dermatology clinics in terms of the requested dermatology consultations during the pandemic. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Temiz, Selami Aykut","Dursun, Recep","Daye, Munise","Ataseven, Arzu"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441360","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/dth.13642","keywords":["covid-19","dermatology consultation","pandemic","teledermatology"],"topics":["Prevention"],"weight":1,"_version_":1667535119503589376,"score":191.98161},{"pmid":32205186,"pmcid":"PMC7102591","title":"COVID-19 infection and rheumatoid arthritis: Faraway, so close!","text":["COVID-19 infection and rheumatoid arthritis: Faraway, so close!","The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients.","Autoimmun Rev","Favalli, Ennio Giulio","Ingegnoli, Francesca","De Lucia, Orazio","Cincinelli, Gilberto","Cimaz, Rolando","Caporali, Roberto","32205186"],"abstract":["The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients."],"journal":"Autoimmun Rev","authors":["Favalli, Ennio Giulio","Ingegnoli, Francesca","De Lucia, Orazio","Cincinelli, Gilberto","Cimaz, Rolando","Caporali, Roberto"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205186","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.autrev.2020.102523","keywords":["covid-19","coronavirus","cytokine release syndrome","dmards","rheumatoid arthritis","treatment"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138490140622848,"score":175.31895}]}